This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Genta Takes Another Stab

The Qnexa data released Wednesday were impressive, especially from an efficacy standpoint, where weight loss exceeded anything seen to date by competing drugs from Arena Pharmaceuticals (ARNA - Get Report) and Orexigen Therapeutics (OREX).

Qnexa will continue to be nagged by worries about safety, primarily the central nervous system side effects of topiramate.

Next up is the second phase III weight-loss study from Arena's drug lorcaserin, which should be released before the end of the month. After that, all three weight-loss drugs, Qnexa, lorcaserin and Orexigen's Contrave, will face the scrutiny of obesity doctors at the Obesity Society annual scientific meeting Oct. 24-28.

Next up, a compliment from Brad L. He writes, "Hey, I just wanted to say thank you for your great work. I'm an individual investor (my investment income is my livelihood) and I just wanted to say I find your articles to be very valuable. Biotech is such a hard thing to invest in because so few people really understand the underlying science (including me) so it is really good to read from someone who clearly gets it. There is so much hype about biotech stocks (I think because of their size and obscurity) that, truthfully, the articles of yours I find most valuable are the ones where you shoot companies down like Antigenics (AGEN - Get Report). Thanks a lot for providing a professional viewpoint. I wanted you to know that there are a lot of real investors out here who really appreciate it."

Fan mail is just as fun to receive as hate mail. Thanks for the kind words, Brad, and thanks for being a reader of mine.
5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $2.13 0.00%
AGEN $5.13 0.00%
OSIR $10.28 0.00%
OPXA $4.09 0.00%
VNDA $9.82 0.00%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs